This site is intended for healthcare professionals

ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DEPO-PROVERA
Bladder, kidney, and other urologic cancers
Gynecologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

DEPO-PROVERA Rx

Generic Name and Formulations:
Medroxyprogesterone acetate 400mg/mL; susp for IM inj.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for DEPO-PROVERA:

As adjunctive and palliative treatment of inoperable, recurrent, and metastatic renal carcinoma.

Adult:

Initially 400–1000mg IM every week. If improvement noted and disease stabilized within a few weeks or months, may be possible to maintain at 400mg per month.

Children:

Not established.

Contraindications:

Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease.

Warnings/Precautions:

Risk of bone mineral density (BMD) loss. Evaluate BMD with long-term use or in adolescents. Family history of breast cancer or who have breast nodules (monitor closely). History of depression; monitor and discontinue if serious depression recurs. Diabetes. Conditions aggravated by fluid retention (eg, migraine, epilepsy, asthma). Cardiac or renal dysfunction. Pretreatment physical exam should include Pap smear and lab tests. May mask onset of climacteric. Monitor hepatic function periodically; temporarily interrupt if hepatic dysfunction develops. Discontinue if jaundice or liver dysfunction, visual disturbances, migraine, or thrombotic disorders occur. Pregnancy. Nursing mothers.

Interactions:

May be antagonized by aminoglutethimide. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's wort). May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.

Pharmacological Class:

Progestin.

Adverse Reactions:

Menstrual irregularities (eg, bleeding, amenorrhea, spotting), nausea, edema/fluid retention, facial swelling, weight gain, dizziness, headache, nervousness, corticoid-like effects, hypersensitivity; decreased BMD, acne, inj site reactions (eg, pain/tenderness, persistent atrophy/indentation/dimpling, nodule/lump).

How Supplied:

Vials (2.5mL)—1

Indications for DEPO-PROVERA:

As adjunctive and palliative treatment of inoperable, recurrent, and metastatic endometrial carcinoma.

Adult:

Initially 400–1000mg IM every week. If improvement noted and disease stabilized within a few weeks or months, may be possible to maintain at 400mg per month.

Children:

Not established.

Contraindications:

Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease.

Warnings/Precautions:

Risk of bone mineral density (BMD) loss. Evaluate BMD with long-term use or in adolescents. Family history of breast cancer or who have breast nodules (monitor closely). History of depression; monitor and discontinue if serious depression recurs. Diabetes. Conditions aggravated by fluid retention (eg, migraine, epilepsy, asthma). Cardiac or renal dysfunction. Pretreatment physical exam should include Pap smear and lab tests. May mask onset of climacteric. Monitor hepatic function periodically; temporarily interrupt if hepatic dysfunction develops. Discontinue if jaundice or liver dysfunction, visual disturbances, migraine, or thrombotic disorders occur. Pregnancy. Nursing mothers.

Interactions:

May be antagonized by aminoglutethimide. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's wort). May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.

Pharmacological Class:

Progestin.

Adverse Reactions:

Menstrual irregularities (eg, bleeding, amenorrhea, spotting), nausea, edema/fluid retention, facial swelling, weight gain, dizziness, headache, nervousness, corticoid-like effects, hypersensitivity; decreased BMD, acne, inj site reactions (eg, pain/tenderness, persistent atrophy/indentation/dimpling, nodule/lump).

How Supplied:

Vials (2.5mL)—1

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.


Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Groin swelling - red flag symptomsExternal web site

This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...

0.50 Credits
Red flags

Erectile dysfunction - red flag symptomsExternal web site

This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...

0.50 Credits
Red flags

Headache - red flag symptomsExternal web site

Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Basal cell carcinoma: clinical reviewExternal web site

In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...

1.50 Credits
Clinical Review

Cardiomyopathy: clinical reviewExternal web site

This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...

1.50 Credits
Clinical Review

Parkinson's disease: clinical reviewExternal web site

Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »